ARS PHARMACEUTICALS INC (SPRY)
Health Care · Specialty biopharmaceuticals / emergency allergy treatment · NASDAQ
Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
What ARS PHARMACEUTICALS INC does
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy (EURneffy/优敏速), a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions and anaphylaxis. Neffy is the company's only approved product, currently available in the United States, EU, United Kingdom, Japan, Australia, China, and Canada. The company is focusing significant resources on commercializing neffy through collaboration partners while developing additional product candidates using intranasal epinephrine technology.
Themes: Anaphylaxis emergency treatment, Needle-free drug delivery, Intranasal epinephrine technology, Allergic reaction management
Fundamentals
- Price$5.51 as of 2026-08-21 close
- Market cap$547M as of 2026-08-21
- 1-year return-63.0% 2025-08-21 close $14.87 → 2026-08-21 close $5.51
- P/En/a negative earnings
- Net margin-200.0% as of 2026-08-24
- Gross margin+74.1% as of 2026-08-24
- ROE-153.6% as of 2026-08-24
- Debt / equity1.57 as of 2026-08-24
- Revenue growth (YoY)+1.9% as of 2026-08-24
- Revenue CAGR (3y)+300.1% SEC XBRL
- Beta0.79 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How SPRY compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ARS PHARMACEUTICALS INC looks technically
ARS PHARMACEUTICALS INC (SPRY) is trading 36.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 221 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 63.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 36.7% below its 200-day average, the long-term trend line — a long-term downtrend | -36.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.26 | $7.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.69 | $8.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 221 trading days ago — a "death cross", a bearish long-term signal | 221 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 28.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($5.00 to $6.58) — its "stochastic" reading is 32 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 32.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.09 | $15.09 |
|---|---|---|
| From the 52-week high | it is 63.5% below its 52-week high (its highest price of the past year) | -63.5% |
| Above the 52-week low | it is 12.1% above its 52-week low (its lowest price of the past year) | +12.1% |
| Below the 52-week high | it is 63.5% below its highest point of the past year | 63.5% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $63.41 (set on 2021-03-18) | $63.41 |
| Given back of the 52-week move | over the past year its closes ranged ($5.13 to $14.87), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.15 to $11.46. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.9% |
| From the all-time high | it is 91.3% below its all-time high | -91.3% |
| Nearest price level | it is trading 39.9% below a resistance level at $7.70 — a price it turned at twice since 2026-04-21, most recently on 2026-04-29. Since 2024-08-21 it has 0 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +39.9% |
| All-time low | its lowest closing price on record is $2.55 (set on 2023-09-20) | $2.55 |
| Above the all-time low | it is 115.9% above its all-time low | +115.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4725 between its high and its low — about 8.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4725 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.08 and $6.46 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.08 – $5.77 – $6.46 |
| Typical daily range (% of price) | its price moves about 8.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.6% |
| Stretch from the 200-day average | it is trading 6.8 daily ranges below its 200-day average price (36.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.55× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 13.1% since the prior reading | -13.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.8% below the previous close 25 sessions ago and has not traded back through the level it left behind at 7.46 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.8% |
| Gap filled | a 16.4% gap down opened on 2026-08-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.8 percentage points (the stock lost 13.4% while the market gained 2.3%) | -15.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 36.2 percentage points (the stock lost 33.1% while the market gained 3.1%) | -36.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 49.9 percentage points (the stock lost 38.8% while the market gained 11.1%) | -49.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 83.5 percentage points (the stock lost 63.0% while the market gained 20.5%) | -83.5% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -34.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 34% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $8.30 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -33.7% |
|---|
Price levels it has turned at before
SPRY last closed at $5.50 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 15 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.70 | Resistance | 39.9% above the last close | turned there twice · 2026-04-21 to 2026-04-29 |
| $8.61 | Resistance | 56.4% above the last close | turned there four times · 2026-02-13 to 2026-04-22 |
| $9.36 | Resistance | 70.0% above the last close | turned there twice · 2025-09-16 to 2025-09-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · Analyst price target recently CUT · lagging the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$23.25 range $17.00 – $30.00; median $23.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SPRY
- Consensus EPS estimate-$0.3033 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Neffy is the company's only approved product; unsuccessful commercialization would materially adversely affect the business and stock price","Company has no prior experience commercializing any product, with significant uncertainty regarding physician and patient adoption of neffy versus traditional epinephrine auto-injectors","Dependence on collaboration partners (ALK Co-Promotion Agreement) for sales force execution; inability to recruit/retain adequate sales personnel or access physicians could hinder market penetration"]
What changed in the latest 10-Q
AI-assisted comparison of SPRY's 10-Q filed 2026-05-15 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference to 10-K filing date changed from 'March 20, 2025' (older, filed 2025-11-10) to 'March 9, 2026' (newer, filed 2026-05-15)
- Reference to fiscal year-end changed from 'December 31, 2024' (older, filed 2025-11-10) to 'December 31, 2025' (newer, filed 2026-05-15)
- Forward-looking statements section reference changed from 'Forward Looking Statements' (older, filed 2025-11-10) to 'Special Note Regarding Forward-Looking Statements' (newer, filed 2026-05-15)
- Text at end of passage changed from 'set forth in the under the caption' (older, filed 2025-11-10) to 'set forth under the caption' (newer, filed 2026-05-15) - grammatical correction
- Notes:
- Both passages are truncated and end mid-sentence, limiting full comparison
- Changes primarily reflect normal updates for a subsequent quarterly filing period
Risk Factors
- Added:
- Reference to neffy approval in UK, Japan, Australia, China and Canada added to first risk factor (2026-05-15 filing)
- Specification that neffy 2 mg and 1 mg approved in Japan and Australia; neffy 2 mg approved in China and Canada (2026-05-15 filing)
- Reference to collaboration agreements extending to 'all other unpartnered geographies outside the United States' rather than just specific jurisdictions (2026-05-15 filing)
- Removed:
- Specific age and weight restrictions for neffy 1 mg and 2 mg in United States (removed in 2026-05-15 filing)
- Detailed EU approval description referencing specific allergen types and idiopathic/exercise-induced anaphylaxis (removed in 2026-05-15 filing)
- Reference to 'Type I allergic reactions' in description of US approval (removed in 2026-05-15 filing)
- Emphasis on 'United States and the EU' as primary focus in opening paragraph of first risk factor (removed in 2026-05-15 filing)
- Reworded:
- First risk factor title changed from 'We are highly dependent on the successful commercialization of neffy in the United States and in the EU' to 'We are highly dependent on the successful commercialization of neffy' (2026-05-15 filing)
- ALK Co-Promotion Agreement changed from 'up to 9,000 specified pediatricians' to 'over 10,000 specified pediatricians' (2026-05-15 filing)
- Collaboration partner name changed from 'CSL Seqirus' to 'Seqirus' for Australia and New Zealand (2026-05-15 filing)
- First risk factor indicator changed from no asterisk to asterisk (*) marking it as new or changed (2026-05-15 filing)
- Reference date in preamble changed from 'March 20, 2025' to 'March 9, 2026' (2026-05-15 filing)
- Notes:
- Text appears truncated at end of both filings; full extent of changes in 'If we are unable to effectively train our sale' section cannot be assessed
- Page numbers differ (48 vs 54), suggesting content repositioning or expansion
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($283550) — 2 selling insiders
- Last 180 days0 buys · 2 sells ($283550) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SPRY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding SPRY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,839,150
- Reported value $87,038,376
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SPRY had 21,451,536 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SPRY had 21.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.78 days to cover at the same settlement.
- Reported short interest (shares) 21,451,536
- Short interest (% of shares outstanding) 21.6%
- Prior settlement (shares) 22,669,317
- Reported change -5.37%
- Days to cover (reported) 7.78
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Mylan (traditional epinephrine auto-injector market)
- Kaléo (emergency epinephrine solutions)
- Adamis Pharmaceuticals (epinephrine products)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
SPRY ranks in…
Frequently asked questions
What does ARS PHARMACEUTICALS INC (SPRY) do?
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy (EURneffy/优敏速), a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions and anaphylaxis. Neffy is the company's only approved product, currently available in the United States, EU, United Kingdom, Japan, Australia, China, and Canada.
What sector is ARS PHARMACEUTICALS INC (SPRY) in?
ARS PHARMACEUTICALS INC (SPRY) is classified in the Health Care sector. Its industry is Specialty biopharmaceuticals / emergency allergy treatment. It trades on NASDAQ.
Who are ARS PHARMACEUTICALS INC's (SPRY) competitors?
Notable peers of ARS PHARMACEUTICALS INC (SPRY) include Mylan (traditional epinephrine auto-injector market), Kaléo (emergency epinephrine solutions) and Adamis Pharmaceuticals (epinephrine products). This peer set is informational only — not financial advice.
Is ARS PHARMACEUTICALS INC (SPRY) overbought or oversold right now?
ARS PHARMACEUTICALS INC (SPRY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SPRY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.